Literature DB >> 23707170

Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Victor A Garcia-Angulo1, Anjana Kalita, Alfredo G Torres.   

Abstract

Enterohemorrhagic Escherichia coli (EHEC) strains are food borne pathogens with importance in public health. EHEC colonizes the large intestine and causes diarrhea, hemorrhagic colitis and in some cases, life-threatening hemolytic-uremic syndrome (HUS) due to the production of Shiga toxins (Stx). The lack of effective clinical treatment, sequelae after infection and mortality rate in humans supports the urgent need of prophylactic approaches, such as development of vaccines. Shedding from cattle, the main EHEC reservoir and considered the principal food contamination source, has prompted the development of licensed vaccines that reduce EHEC colonization in ruminants. Although murine models do not fully recapitulate human infection, they are commonly used to evaluate EHEC vaccines and the immune/protective responses elicited in the host. Mice susceptibility differs depending of the EHEC inoculums; displaying different mortality rates and Stx-mediated renal damage. Therefore, several experimental protocols have being pursued in this model to develop EHEC-specific vaccines. Recent candidate vaccines evaluated include those composed of virulence factors alone or as fused-subunits, DNA-based, attenuated bacteria and bacterial ghosts. In this review, we summarize progress in the design and testing of EHEC vaccines and the use of different strategies for the evaluation of novel EHEC vaccines in the murine model.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23707170      PMCID: PMC3691335          DOI: 10.1016/j.vaccine.2013.05.013

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  95 in total

1.  Hierarchical delivery of an essential host colonization factor in enteropathogenic Escherichia coli.

Authors:  Nikhil A Thomas; Wanyin Deng; Noel Baker; Jose Puente; B Brett Finlay
Journal:  J Biol Chem       Date:  2007-08-06       Impact factor: 5.157

2.  Immune responses of mice immunized with active recombinant shiga toxin and its derivatives.

Authors:  Mana Oloomi; Saeid Bouzari; Soheila Ajdary
Journal:  Iran J Allergy Asthma Immunol       Date:  2008-06       Impact factor: 1.464

3.  Bovine immune response to shiga-toxigenic Escherichia coli O157:H7.

Authors:  Mark A Hoffman; Christian Menge; Thomas A Casey; William Laegreid; Brad T Bosworth; Evelyn A Dean-Nystrom
Journal:  Clin Vaccine Immunol       Date:  2006-10-18

4.  A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2.

Authors:  Takao Tsuji; Takeshi Shimizu; Keiko Sasaki; Kentaro Tsukamoto; Hideyuki Arimitsu; Sadayuki Ochi; Toshiyasu Shimizu; Koki Taniguchi; Masatoshi Noda; Paola Neri; Hiroshi Mori
Journal:  Vaccine       Date:  2008-03-07       Impact factor: 3.641

5.  Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant.

Authors:  Angel Cataldi; Tetyana Yevsa; Daniel A Vilte; Kai Schulze; Mauricio Castro-Parodi; Mariano Larzábal; Cristina Ibarra; Elsa C Mercado; Carlos A Guzmán
Journal:  Vaccine       Date:  2008-09-21       Impact factor: 3.641

6.  Subcutaneous and intranasal immunization with type III secreted proteins can prevent colonization and shedding of Escherichia coli O157:H7 in mice.

Authors:  Shawn Babiuk; David J Asper; Dragan Rogan; George K Mutwiri; Andrew A Potter
Journal:  Microb Pathog       Date:  2008-03-26       Impact factor: 3.738

7.  An investigation of the expression and adhesin function of H7 flagella in the interaction of Escherichia coli O157 : H7 with bovine intestinal epithelium.

Authors:  Arvind Mahajan; Carol G Currie; Shona Mackie; Jai Tree; Sean McAteer; Iain McKendrick; Tom N McNeilly; Andrew Roe; Roberto M La Ragione; Martin J Woodward; David L Gally; David G E Smith
Journal:  Cell Microbiol       Date:  2008-10-30       Impact factor: 3.715

Review 8.  Verocytotoxin-producing Escherichia coli (VTEC).

Authors:  Mohamed A Karmali; Victor Gannon; Jan M Sargeant
Journal:  Vet Microbiol       Date:  2009-04-10       Impact factor: 3.293

9.  Development of an experimental hemolytic uremic syndrome in rats.

Authors:  Elsa Zotta; Nestor Lago; Federico Ochoa; Horacio A Repetto; Cristina Ibarra
Journal:  Pediatr Nephrol       Date:  2008-02-06       Impact factor: 3.714

10.  An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their dissemination.

Authors:  Toru Tobe; Scott A Beatson; Hisaaki Taniguchi; Hiroyuki Abe; Christopher M Bailey; Amanda Fivian; Rasha Younis; Sophie Matthews; Olivier Marches; Gad Frankel; Tetsuya Hayashi; Mark J Pallen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-21       Impact factor: 11.205

View more
  19 in total

Review 1.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Immunization of mice with chimeric antigens displaying selected epitopes confers protection against intestinal colonization and renal damage caused by Shiga toxin-producing Escherichia coli.

Authors:  David A Montero; Felipe Del Canto; Juan C Salazar; Sandra Céspedes; Leandro Cádiz; Mauricio Arenas-Salinas; José Reyes; Ángel Oñate; Roberto M Vidal
Journal:  NPJ Vaccines       Date:  2020-03-12       Impact factor: 7.344

3.  Exploiting the power of OMICS approaches to produce E. coli O157 vaccines.

Authors:  Anjana Kalita; Mridul Kalita; Alfredo G Torres
Journal:  Gut Microbes       Date:  2014

4.  In silico analysis of Shiga toxins (Stxs) to identify new potential vaccine targets for Shiga toxin-producing Escherichia coli.

Authors:  Maryam Golshani; Mana Oloomi; Saeid Bouzari
Journal:  In Silico Pharmacol       Date:  2017-05-22

5.  Nano-multilamellar lipid vesicles (NMVs) enhance protective antibody responses against Shiga toxin (Stx2a) produced by enterohemorrhagic Escherichia coli strains (EHEC).

Authors:  M J Rodrigues-Jesus; W L Fotoran; R M Cardoso; K Araki; G Wunderlich; Luís C S Ferreira
Journal:  Braz J Microbiol       Date:  2018-12-06       Impact factor: 2.476

Review 6.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01

7.  Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7.

Authors:  Víctor A García-Angulo; Anjana Kalita; Mridul Kalita; Luis Lozano; Alfredo G Torres
Journal:  Infect Immun       Date:  2014-03-04       Impact factor: 3.441

Review 8.  Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype.

Authors:  Elias A Rahal; Sukayna M Fadlallah; Farah J Nassar; Natalie Kazzi; Ghassan M Matar
Journal:  Front Cell Infect Microbiol       Date:  2015-03-18       Impact factor: 5.293

Review 9.  Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-Producing Escherichia coli.

Authors:  Su-Bin Hwang; Ramachandran Chelliah; Ji Eun Kang; Momna Rubab; Eric Banan-MwineDaliri; Fazle Elahi; Deog-Hwan Oh
Journal:  Front Cell Infect Microbiol       Date:  2021-06-29       Impact factor: 5.293

10.  From In silico Protein Epitope Density Prediction to Testing Escherichia coli O157:H7 Vaccine Candidates in a Murine Model of Colonization.

Authors:  Daniel Tapia; Brittany N Ross; Anjana Kalita; Mridul Kalita; Christopher L Hatcher; Laura A Muruato; Alfredo G Torres
Journal:  Front Cell Infect Microbiol       Date:  2016-08-30       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.